Larry D Lynd1, Anthony Traboulsee2, Carlo A Marra3, Nicole Mittmann4, Charity Evans5, Kathy H Li6, Melanie Carter6, Celestin Hategekimana6. 1. Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, Canada V6T 1Z3. 2. Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada. 3. School of Pharmacy, Memorial University of Newfoundland, St John's, Canada. 4. Sunnybrook Research Institute, Toronto, Canada. 5. College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Canada. 6. Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Canada.
Abstract
BACKGROUND: With recent developments in drug therapy for multiple sclerosis (MS), new treatment options have become available presenting patients with complex treatment decisions. OBJECTIVES: The objective of this study was to elicit patients' preferences for different attributes of MS drug therapy. METHODS: A representative sample of patients with MS across Canada (n=189) participated in a best-worst scaling study to quantify preferences for different attributes of MS drug therapy, including delaying progression, improving symptoms, preventing relapse, minor side effects, rare but serious adverse events (SAEs), and route of administration. Conditional logit models were fitted to estimate the relative importance of each attribute in influencing patients' preferences. RESULTS: A latent-class analysis revealed heterogeneity of preferences across respondents, with preferences differing across five classes. The most important attributes of drug therapy were the avoidance of SAEs for three classes and the improvement of symptoms for two other classes. Only a smaller group of patients demonstrated a specific preference for avoiding SAEs, and route of administration. CONCLUSION: This study shows that preferences for drug therapy among patients with MS are different, some of which can be explained by experiences with their disease and treatment. These findings can help to inform the focus of interactions that healthcare practitioners have with patients with MS, as well as further drug development.
BACKGROUND: With recent developments in drug therapy for multiple sclerosis (MS), new treatment options have become available presenting patients with complex treatment decisions. OBJECTIVES: The objective of this study was to elicit patients' preferences for different attributes of MS drug therapy. METHODS: A representative sample of patients with MS across Canada (n=189) participated in a best-worst scaling study to quantify preferences for different attributes of MS drug therapy, including delaying progression, improving symptoms, preventing relapse, minor side effects, rare but serious adverse events (SAEs), and route of administration. Conditional logit models were fitted to estimate the relative importance of each attribute in influencing patients' preferences. RESULTS: A latent-class analysis revealed heterogeneity of preferences across respondents, with preferences differing across five classes. The most important attributes of drug therapy were the avoidance of SAEs for three classes and the improvement of symptoms for two other classes. Only a smaller group of patients demonstrated a specific preference for avoiding SAEs, and route of administration. CONCLUSION: This study shows that preferences for drug therapy among patients with MS are different, some of which can be explained by experiences with their disease and treatment. These findings can help to inform the focus of interactions that healthcare practitioners have with patients with MS, as well as further drug development.
Authors: Dimitris Potoglou; Peter Burge; Terry Flynn; Ann Netten; Juliette Malley; Julien Forder; John E Brazier Journal: Soc Sci Med Date: 2011-04-05 Impact factor: 4.634
Authors: Leslie S Wilson; Aimee Loucks; Gregory Gipson; Lixian Zhong; Christine Bui; Elizabeth Miller; Mary Owen; Daniel Pelletier; Douglas Goodin; Emmanuelle Waubant; Charles E McCulloch Journal: Int J MS Care Date: 2015 Mar-Apr
Authors: Camila Guimarães; Carlo A Marra; Sabrina Gill; Scot Simpson; Graydon Meneilly; Regina Hc Queiroz; Larry D Lynd Journal: Patient Prefer Adherence Date: 2010-12-08 Impact factor: 2.711
Authors: Edward J D Webb; David Meads; Ieva Eskyte; Natalie King; Naila Dracup; Jeremy Chataway; Helen L Ford; Joachim Marti; Sue H Pavitt; Klaus Schmierer; Ana Manzano Journal: Patient Date: 2018-08 Impact factor: 3.883
Authors: Edward J D Webb; David Meads; Ieva Eskytė; Helen L Ford; Hilary L Bekker; Jeremy Chataway; George Pepper; Joachim Marti; Yasmina Okan; Sue H Pavitt; Klaus Schmierer; Ana Manzano Journal: Patient Date: 2020-10 Impact factor: 3.883
Authors: Larry D Lynd; Natalie J Henrich; Celestin Hategeka; Carlo A Marra; Nicole Mittmann; Charity Evans; Anthony L Traboulsee Journal: Int J MS Care Date: 2018 Nov-Dec
Authors: Rafael Arroyo; Angel P Sempere; Elena Ruiz-Beato; Daniel Prefasi; Agata Carreño; Montse Roset; Jorge Maurino Journal: BMJ Open Date: 2017-03-08 Impact factor: 2.692
Authors: Marco Kaufmann; Jens Kuhle; Milo A Puhan; Christian P Kamm; Andrew Chan; Anke Salmen; Jürg Kesselring; Pasquale Calabrese; Claudio Gobbi; Caroline Pot; Nina Steinemann; Stephanie Rodgers; Viktor von Wyl Journal: Mult Scler J Exp Transl Clin Date: 2018-12-06
Authors: Nick Bansback; Judy A Chiu; Rebecca Metcalfe; Emmanuelle Lapointe; Alice Schabas; Marilyn Lenzen; Anthony Traboulsee; Larry D Lynd; Robert Carruthers Journal: Mult Scler J Exp Transl Clin Date: 2021-07-15